Guidance revision urges sponsors to use “an anchor-based approach, typically using Phase II trial data, to estimate clinically meaningful change” when defining endpoints.
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
